Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity.
Dahlsson Leitao C, Mestre Borras A, Xu T, Oroujeni M, Liu Y, Westerberg C, Clinton J, Tolmachev V, Orlova A, Ståhl S, Vorobyeva A, Löfblom J.
Dahlsson Leitao C, et al. Among authors: mestre borras a.
J Control Release. 2023 May;357:185-195. doi: 10.1016/j.jconrel.2023.03.046. Epub 2023 Mar 31.
J Control Release. 2023.
PMID: 36990160
Free article.